Literature DB >> 25471755

The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency--the first experience.

A Árokszállási1, A Kerényi, É Katona, Z Bereczky, L Muszbek, Z Boda, Á Schlammadinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25471755     DOI： 10.1111/hae.12591

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

1.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

2.  Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

Authors:  Manuel Carcao; Carmen Altisent; Giancarlo Castaman; Katsuyuki Fukutake; Bryce A Kerlin; Craig Kessler; Riitta Lassila; Diane Nugent; Johannes Oldenburg; May-Lill Garly; Anders Rosholm; Aida Inbal
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

3.  Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence.

Authors:  Lone Hvitfeldt Poulsen; Bryce A Kerlin; Giancarlo Castaman; Angelo Claudio Molinari; Marzia Menegatti; Diane Nugent; Sohan Dey; May-Lill Garly; Manuel Carcao
Journal:  Res Pract Thromb Haemost       Date:  2022-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.